初始低剂量氨氯地平加替米沙坦或复方阿米洛利联合治疗对高.docVIP

初始低剂量氨氯地平加替米沙坦或复方阿米洛利联合治疗对高血压患者血压 控制率的影响- CHIEF：中国高血压干预效果研究早期阶段报告-2 王文 马丽媛* 刘明波 邓卿 张宇清 李卫 刘力生代表CHIEF研究协作组 摘要：目的：探讨以氨氯地平为基础的联合治疗方案，对高血压患者血压达标及对心血管事件的影响。对象和方法：50～79岁伴心血管病危险因素的高血压患者知情同意后进入研究。这是一项多中心随机开放对照盲终点评估的临床试验，随机分为低剂量氨氯地平＋复方阿米洛利组（A组）或氨氯地平＋替米沙坦组（T组），主要终点是心血管病复合事件，治疗随访4年。阶段结果：2007年10月至2008年10月，180家合作单位共随机13542例患者。A组（n=6776）和T组（n=6766）患者基线临床特征相似：平均年龄均为61.5±7.7岁，脑血管病史占19%、冠心病病史占12%，糖尿病占18%，血脂异常占42%，平均血压水平为157/93mmHg。随机治疗后第8周A组与T组血压均降至133/80mmHg，血压较前下降24/13mmHg；血压控制率分别达72.1％和72.6％。结论：早期阶段资料分析提示本研究随机良好；以氨氯地平为基础的联合降压治疗血压控制率较高。 关键词： 高血压，联合治疗，血压控制, 临床试验 （国家十一五科技支撑计划课题：课题号 2006BAI01A03） Effects of initial low-dose amlodipine-based combination treatment on blood pressure control in hypertensive patients -Preliminary report of CHIEF : Chinese Hypertension Intervention EFficacy study Wang Wen, Ma Liyuan, Liu Mingbo，Deng Qing, Zhang Yuqing, Li Wei, Liu Lisheng. For CHIEF Coorperative Group Cardiovascular Institute and Fuwai Hospital, CAMS PUMC, National center for cardiovascular disease，China. 100037 Beijing Aim: To evaluate the effects of amlodipine-based antihypertensive combination treatment on the blood pressure control goals and cardiovascular events. Subject and Methods: Patients are eligible for inclusion in the study if they are essential hypertension, 50-79 years of age with at least one cardiovascular risk factor and sign the consent forms. This project is a multi-centre randomized, controlled，blind-endpoint assessment clinical trial. Patients are randomly assigned to low-dose amlodipine+diuretics (group A) or amlodipine+ telmisartan (group T). The primary endpoints are composite of non-fatal stroke/myocardial infarction and cardiovascular death. All patients will be followed-up for 4 years. Preliminary results: From Oct. 2007 to Oct. 2008, a total of 13542 patients have been randomized into study from 180 centres in China. The characteristics of patients in both Group A and group T were similar: mean age 61.5±7.7 Yrs，history of cerebrovascular diseases 19